研究队伍
院士专家
青年千人
百人计划
杰出青年
研究员
副研究员
人才招聘
现在位置::首页 > 研究队伍

姓  名:
周光飚
学  科:
细胞生物学
电话/传真:
+86-10-64807951 / +86-10-64807150
电子邮件:
gbzhou@ioz.ac.cn
通讯地址:
北京市朝阳区北辰西路1号院5号
中国科学院动物研究所 膜生物学国家重点实验室 100101
更多信息:
肿瘤分子机理与靶向疗法研究组     
简历:

  周光飚,博士,中国科学院动物研究所二级研究员,膜生物学国家重点实验室肿瘤分子机理与靶向疗法研究组组长,中国科学院大学岗位教授,中国科学技术大学兼职博导,国家杰出青年科学基金获得者。Frontiers of Medicine杂志执行副主编,Austin Journal of Lung Cancer Research、International Journal of Hematology Research、Austin Pathology杂志编委,中国抗癌协会肿瘤转移专业委员会委员、中国转化医学联盟第一届理事会理事、中国病理生理学会实验血液学专业委员会第7届委员,美国癌症研究学会会员、美国血液学会会员。主要研究空气污染、 吸烟引起肺癌的机理及中药抗肿瘤药理,在Elife、EBioMedicine、PNAS、Blood、Oncotarget、Carcinogenesis、Science Translational Medicine、Science等杂志发表论文70篇,参编专著4部,参译书籍1部,12 项专利获得授权。J Prot Res、Oncotarget、Mol Cancer、Int J Cancer、Tobacco Induced Diseases、Lung Cancer等杂志特约审稿人,被评为Cancer Letters杂志的Outstanding reviewer。
  已毕业研究生16人,目前实验室有在读研究生11人(硕士生4人,博士生7人)。 迄今课题组已有1人获中国科学技术大学研究生国家奖学金,2人获中国科学院朱李月华优秀博士生奖,2人获地奥奖学金,1人获中国科学院大学生奖学金,1人被评为中科院研究生院优秀学生干部,1名被评为三好学生,2名被评为优秀党员。

科研工作经历:
  2009 - 现 在 研究员, 中国科学院动物研究所生物膜与膜工程国家重点实验室
  2007 - 现 在 博 导, 中国科学技术大学
  2005 - 2009  研究员, 中科院广州生物医药与健康研究院
  2003 - 2005  博士后, 中国科学院上海生命科学研究院
  1993 - 1997  医 师, 广西桂林铁路医院

主要学历:
  2000-2003 博士研究生,上海交通大学医学院,专业方向:内科学
  1997-2000 硕士研究生,中南大学湘雅医学院,专业方向:内科学
  1988-1993 学士,广西医科大学,专业方向:临床医学

研究领域:

  肺癌发病机理(Molecular pathogenesis of non-small cell lung cancer);中药抗肿瘤药理(mechanisms of action of Traditional Chinese Medicine in treating cancer) 。

社会任职:
  Frontiers of Medicine杂志执行副主编
  中国抗癌协会肿瘤转移专业委员会委员
  中国病理生理学会实验血液学专业委员会第7届委员
  中国转化医学联盟第一届理事会理事
  Austin Journal of Lung Cancer Research 编委
  International Journal of Hematology Research 编委
  Austin Pathology编委
  美国癌症研究学会会员
  美国血液学会会员
获奖及荣誉:
  曾获中国科学院王宽诚博士后工作奖励金、中国博士后科学基金,被评为中国科学院广州生物医药与健康研究院先进共产党员、先进工作者、中国科学院广州教育基地优秀研究生导师、中国科学院广州分院优秀共产党员、广东省省直机关优秀共产党员。 
承担科研项目情况:
  • 国家杰出青年科学基金(2015-2019):中药抗肿瘤药理;
  • 国家科技部资助“973”项目(2012-2016):炎症诱导肿瘤的分子调控网络研究,课题骨干;
  • 国家自然科学基金(2012-2015):环境致癌物苯并芘灭活PTEN 的 机制研究;项目负责人;
  • 国家自然科学基金(2011-2013):CIP2A与肺癌发生及作为治疗新靶点的实验研究;项目负责人;
  • 国家科技部资助“973”项目(2010-2014):基于系统生物医学基础的白血病临床转化研究,分课题负责人;
代表论著:
  1. Wang GZ, Cheng X, Zhou B, Wen ZS, Huang YC, Chen HB, Li GF, Huang ZL, Zhou YC, Feng L, Wei MM, Qu LW, Cao Y, Zhou GB. The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution, eLIFE, 2015; 4:e09419.
  2. Liu YQ, Wang XL, Cheng X, Lu YZ, Wang GZ, Li XC, Zhang J, Wen ZS, Huang ZL, Gao QL, Yang LN, Cheng YX, Tao SC, Liu J, Zhou GB. Skp1 in lung cancer: Clinical significance and therapeutic efficacy of its small molecule inhibitors. Oncotarget, 2015; 6:34953-34967
  3. Wang GZ, Cheng X, Li XC, Liu YQ, Wang XQ, Shi X, Wang ZY, Guo YQ, Wen ZS, Huang YC, Zhou GB. Tobacco smoke induces production of chemokine CCL20 to promote lung cancer. Cancer Letters, 2015; 363:60-70
  4. Pan HL, Wen ZS, Huang YC, Cheng X, Wang GZ, Zhou YC, Wang ZY, Guo YQ, Cao Y, Zhou GB. Down-regulation of microRNA-144 in air pollution-related lung cancer. Sci Rep, 2015; 5:14331.
  5. Wang GZ, Liu YQ, Cheng X, Zhou GB. Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents. Cancer Science, 2015; 106(7):902-908
  6. Yu XJ, Yang MJ, Zhou B, Wang GZ, Huang YC, Wu LC, Cheng X, Wen ZS, Huang JY, Zhang YD, Gao XH, Li GF, He SW, Gu ZH, Ma L, Pan CM, Wang P, Chen HB, Hong ZP, Wang XL, Mao WJ, Jin XL, Kang H, Chen ST, Zhu YQ, Gu WY, Liu Z, Dong H, Tian LW, Chen SJ, Cao Y, Wang SY, Zhou GB. Characterization of Somatic Mutations in Air Pollution-Related Lung Cancer, EBioMedicine, 2015; 2:583-590.
  7. Li J, Zhong HY, Zhang Y, Xiao L, Bai LH, Liu SF, Zhou GB, Zhang GS. GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid. Br J Haematol, 2015;168:904-908.
  8. Mi JQ, Chen SJ, Zhou GB, Yan XJ, Chen Z. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. J Intern Med, 2015; 278:627-42.
  9. Mandel JH, Wendt C, Lo C, Zhou G, Hertz M, Ramachandran G. Ambient air pollution and lung disease in China: health effects, study design approaches and future research. Front Med, 2015; 9:392-400.
  10. Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W, Liu J, Zhou GB. Cancerous inhibitor of PP2A (CIP2A) is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis, 2014; 35: 905-914.
  11. Liu Z, Ma L, Wen ZS, Cheng YX, Zhou GB*. Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells. ACS Med Chem Lett, 2014; 5: 113 - 118.
  12. Liu Y, Xiao Q, Liu Y, Li Z, Qiu Y, Zhou G, Yao Z, Jiang S. Biological evaluation of new mimetics of annonaceous acetogenins: Alteration of right scaffold by click linkage with aromatic functionalities. Eur J Med Chem, 2014; 78: 248–258.
  13. Liu Y, Liu Y, Li Z, Zhou GB, Yao ZJ, Jiang S. Identification of novel bivalent mimetics of annonaceous acetogenins via a scaffold-hopping strategy. Bioorg Med Chem Lett 2014; 24:1650-1653.
  14. Zhou G, Chen Z. Translating the power of TCM into patients' hope. Front Med 2014; 8: 265-267
  15. Wu LC, Wen ZS, Qiu YT, Chen XQ, Chen HB, Wei MM, Liu Z, Jiang S, Zhou GB. Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells. ACS Med Chem Lett, 2013; 4: 921-926.
  16. Liu JL, Zeng GZ, Liu XL, Liu YQ, Hu ZG, Liu Y, Tan NH, Zhou GB. Small compound bigelovin exerts inhibitory effects and triggers proteolysis of E2F1 in multiple myeloma cells. Cancer Sci, 2013;104: 1697-1704.
  17. Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu YP, Yu XJ, Zhang XD, Ming PH, Zhou GB, Huang L.. The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. Sci Rep, 2013; 3: 3098.
  18. Zhang B, Jiao J, Liu Y, Guo LX, Zhou B, Li GQ, Yao ZJ, Zhou GB. Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa. PLoS ONE, 2012;7:e47049.
  19. Yu XJ, Han QB, Wen ZS, Ma L, Gao J, Zhou GB. Gambogenic acid induces G1 arrest via GSK3β-dependent Cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett, 2012; 322:185-194.
  20. Fang HT, Zhang B, Pan XF, Gao L, Zhen T, Zhao HX, Ma L, Xie J, Liu Z, Yu XJ, Cheng X, Feng TT, Zhang FX, Yang Y, Hu ZG, Sheng GQ, Chen YL, Chen SJ, Chen Z, Zhou GB. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci U S A, 2012; 109: 2521-2526.
  21. Liu YQ, Cheng X, Guo LX, Mao C, Chen YJ, Liu HX, Xiao QC, Jiang S, Yao ZJ, Zhou GB. Identification of an annonaceous acetogenin mimetic, AA005, as an AMPK activator and autophagy inducer in colon cancer cells. PLoS ONE, 2012; 7: e47049.
  22. Zhen T, Wu CF, Liu P, Wu HY, Zhou GB, Lu Y, Liu JX, Liang Y, Li KK, Wang YY, Xie YY, He MM, Cao HM, Zhang WN, Chen LM, Petrie K, Chen SJ, and Chen Z. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med, 2012;4:127ra38.
  23. Quan J, Johnson N, Zhou G, Parsons P, Boyle G, Gao J. Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms. Cancer and Metastasis Reviews, 2012; 31: 209-219.
  24. Liu JX, Zhou GB, Chen SJ, Chen Z. Arsenic compounds: revived ancient remedies in the fight against human malignancies. Current Opinion in Chemical Biology, 2012; 16:92-98.
  25. Chen SJ, Zhou GB. Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond. IUBMB Life. 2012; 64:671-675.
  26. Xiao Y, Shao Y, Yu X, Zhou G. The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China. Front Med, 2012; 6:388-94.
  27. Ma L, Wen ZS, Hu Z, Liu Z, Ma J, Chen XQ, Liu YQ, Pu JX, Xiao WL, Sun HD, Zhou GB. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS ONE, 2011; 6:e20159.
  28. Liu Z, Ma L, Zhou GB. The main anticancer bullets of the Chinese medicinal herb, thunder god vine. Molecules, 2011;16:5283-5297.
  29. Liu Y, Chen XQ, Liang HX, Zhang FX, Zhang B, Jin J, Chen YL, Cheng YX, Zhou GB. Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. PLoS ONE, 2011; 6: e21930.
  30. Zhou GS, Hu Z, Fang HT, Zhang FX, Pan XF, Chen XQ, Hu AM, Xu L, Zhou GB. Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk Res, 2011; 35: 214-218.
  31. Chen SJ, Zhou GB, Zhang XW, Mao JH, de The H, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011;117:6425-6437.
  32. Chen Z, Zhou G. Translational medicine should translate medical science and technology into health care for everyone in China. Science China Life Science, 2011; 54:1074-1076.
  33. Xiao Q, Liu Y, Qiu Y, Yao Z, Zhou G, Yao ZJ, Jiang S. Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities. Bioorgan Med Chem Lett, 2011;21:3613-3615.
  34. Wu W, Li Z, Zhou G, Jiang S. Total synthesis of argyrins A and E. Tetrahedron Letters 2011; 52: 2488-2491.
  35. Zeng X, Yin BL, Hu Z, Liao CZ, Liu JL, Li S, Li Z, Nicklaus MC, Zhou GB, Jiang S. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells. Org Lett, 2010;12:1368-1371.
  36. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 2010; 328: 240-243.
  37. Xiao Q, Liu Y, Qiu Y, Zhou G, Mao C, Li Z, Yao ZJ, Jiang S. Potent Antitumor Mimetics of Annonaceous Acetogenins Embedded with an Aromatic Moiety in the Left Hydrocarbon Chain Part. J Med Chem, 2010;54:525-533.
  38. Chen SJ, Chen XP, Zhou GB. Healthy people, healthy journal. Frontiers of Medicine in China, 2010; 4:1-2.
  39. Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, Liu Y, Feng TT, Meng FY, Liu XL, Jiang QL, Chen XQ, Liu JL, Liu P, Chen Z, Chen SJ, Zhou GB. Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS ONE. 2009; 4:e6257.
  40. Ding LF, Liu Y, Liang HX, Liu DP, Zhou GB, Cheng YX. Two new terpene glucosides and antitumor agents from Centipeda minima. Journal of Asian Natural Products Research, 2009; 11:732-736.
  41. Zeng GZ, Tan NH, Ji CJ, Fan JT, Huang HQ, Han HJ, Zhou GB. Apoptosis inducement of bigelovin from Inula helianthus-aquatica on human leukemia U937 cells. Phytother Res, 2009; 23:885-891.
  42. Hu J, Liu YF, Wu QF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 2009; 106:3342-3347.
  43. 方海同, 胡政, 周光飚. 一种基于绿色荧光蛋白的蛋白酶体抑制剂细胞筛选模型. 生物工程学报, 2009; 25: 452-456.
  44. 冯婷婷, 普建新, 胡政, 刘大鹏, 孙汉董, 周光飚. 二萜化合物Rabdocoetsin B抑制蛋白酶体功能并诱导t(8;21)白血病细胞凋亡. 生物工程学报, 2009; 25: 1218-1224.
  45. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A, 2008;105:4826-4831.
  46. 陈竺, 陈赛娟, 周光飚. 实验血液学架起实验室与临床的桥梁-血液学的希望. 中国实验血液学杂志, 2008; 16: 1-21.
  47. Chen SJ, Zhou GB, Bai XT, Chen Z. Nucleoporin. In: Schwab M, ed. Encyclopedia of Cancer: Springer Berlin Heidelberg; 2008:2124-2126.
  48. Shen Y, Xu Q, Han Z, Liu H, Zhou GB. Analysis of phenotype-genotype connection: the story of dissecting disease pathogenesis in genomic era in China, and beyond. Philos Trans R Soc Lond B Biol Sci, 2007; 362:1043-1061.
  49. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood, 2007;109:3441-3450.
  50. Zhou G, Zhang J, Wang Z, Chen S, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil Trans R Soc B, 2007;362:959-971.
  51. Zhou GB, Li G, Chen SJ, Chen Z. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta Pharmacol Sin 2007; 28:1434-1449.
  52. Zhou GB, Chen SJ, Wang ZY, Chen Z. Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res, 2007;17:274-276.
  53. Hu J, Zhou GB, Wang ZY, Chen SJ, Chen Z. Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond. Adv Cancer Res, 2007; 98:191-220.
  54. Wang L, Zhao WL, Yan JS, Liu P, Sun HP, Zhou GB, Weng ZY, Wu WL, Weng XQ, Sun XJ, Chen Z, Sun HD, Chen SJ. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ, 2007;14:306-317.
  55. 扶云碧,孙启鑫,孟凡义,谢军,周光飚. 蛋白酶体抑制剂硼替佐米诱导髓系白血病细胞株HL60凋亡的机制研究. 中华医学杂志, 2006; 86: 2413-2416.
  56. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ.. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A, 2005;102:1104-1109.
  57. Zhou GB, Zhao WL, Wang ZY, Chen SJ, Chen Z. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Medicine, 2005; 2:33-38.
  58. Zhou GB, Zhao WL, Wang ZY, Chen SJ, Chen Z. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Medicine, 2005;2:33-38.
  59. 陈丽娟,董颖,陈思宇,张龙,周光飚,陈冰,王龙,陈竺,陈赛娟. PLZF-RARα/RARα-PLZF双阳性转基因小鼠发生白血病模型研究. 中国实验血液学杂志, 2005; 13: 924-931.
  60. Zhang GS, Zhou GB, Dai CW. Upregulation and activation of caspase-3 or caspase-8 and elevation of intracellular free calcium mediated apoptosis of indomethacin-induced K562 cells. Chin Med J (Engl), 2004;117:978-984.
  61. 周光飚, 董颖,王月英,印彤,亢卉,陈竺,陈赛娟. 白血病致病基因产物靶向治疗:从急性早幼粒到其他类型白血病. 中国科学(C辑). 2004, 34: 487-500.
  62. 董颖,陈丽娟,陈思宇,张龙,周光飚,王龙,陈赛娟. hCG/RARα/PLZF转基因小鼠发生髓系增殖性疾病. 中华血液学杂志, 2004, 25: 745-747.
  63. 周光飚. 对八纲辨证发展的思考. 中国中西医结合杂志, 2002; 22: 233-234.
  64. 周光飚,王振义.诱导分化治疗急性白血病的研究进展.中华血液学杂志, 2002; 23(1): 49-51.
  65. 周光飚, 张广森. 吲哚美辛诱导K562细胞凋亡过程中半胱天冬酶及细胞内游离钙浓度的变化. 中华血液学杂志, 2001; 21: 241-244.
  66. Zhang G, Tu C, Zhang G, Zhou G, Zheng W. Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leuk Res 2000;24:385-392.
  67. 周光飚. Caspase家族与细胞凋亡调控. 国外医学分子生物学分册, 2000; 22:167-170.
  68. 周光飚. Caspase家族在恶性血液病的表达及意义研究进展. 国外医学输血及血液学分册, 1999; 22: 394-396.
  69. 周光飚. 肿瘤具有两面性吗. 医学与哲学, 1999; 20: 19-20.
  70. 周光飚. 端粒-端粒酶系统与血液系统恶性肿瘤. 国外医学输血及血液学分册, 1998; 21: 406-410.
  71. 周光飚. 弓形虫病1例. 临床荟萃, 1996; 11: 192.
  72. 周光飚. 炸药外洗致溶血1例. 中国实用内科杂志, 1996; 16: 554.
写给考生的话:
  攻读硕士/博士学位是人生的重要经历,可以提高自身素质,也可以改变人生方向。希望有志者珍惜时间,踏实努力,勇于创新,取得成果,实现自己的理想与价值。